UNLABELLED: The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies. CONCLUSION: While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed.
UNLABELLED: The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies. CONCLUSION: While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed.
Authors: Maria Grazia Pascucci; Valentina Di Gregori; Gabriella Frasca; Paola Rucci; Alba Carola Finarelli; Laura Moschella; Bianca Maria Borrini; Francesca Cavrini; Giovanna Liguori; Vittorio Sambri; Paolo Bonanni; Maria Pia Fantini Journal: Hum Vaccin Immunother Date: 2013-12-30 Impact factor: 3.452
Authors: Patricia Kaaijk; Arie van der Ende; Guy Berbers; Germie P J M van den Dobbelsteen; Nynke Y Rots Journal: BMC Infect Dis Date: 2012-02-08 Impact factor: 3.090